IRadimed is perceived positively due to its growing ROCE and the ability to profitably reinvest capital, which has also started to reap benefits for its shareholders. Regardless of the promising performance, further due diligence is recommended for the company.
IRadimed股票讨论
新增数据:23Q2,23Q3,23Q4,营收、营业利润和净利润持续增长。
2023年营收增长23%,营业利润增长28.2%,净利润增长34%,净资产收益率提高到了23.7%。
资产负债率从13.9%提高到了22.5%,总资产有增加,但是净资产反而减少了。资产端现金流向了存货,固定资产有所增加,负债端应付款项大幅增加,属于良性负债。
目前市盈率31.33,和增速比估值并不算高,依然可以谨慎选择(⭐️)
📊⚡️📊
暂无评论